[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-regeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-regeneration":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,54,82,110,139,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":28,"conditions":29,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100632003","phase-1-evaluation-of-stem-cell-exosomes-versus-platelet-rich-fibrin-in-tooth-extraction-socket-healing-100632003",false,"NCT07508033","Evaluation of Stem Cell Exosomes Versus Platelet-Rich Fibrin in Tooth Extraction Socket Healing","Evaluation of Mesenchymal Stem Cell-Derived Exosomes Versus Platelet-Rich Fibrin (PRF) in Post-Extraction Socket Healing: A Randomized Controlled Clinical Trial.","MSC-EXO vs PRF","Inclusion Criteria:\n\n* Patients aged between 20 and 45 years.\n* Patients requiring a single tooth extraction of a non-infected tooth in the aesthetic zone (incisors, canines) or premolar area.\n* Presence of adjacent teeth to the extraction site.\n* Adequate oral hygiene (Plaque Index \\\u003C 20%).\n* Patients willing and able to comply with the follow-up schedule and 3-month CBCT scan.\n* Signed informed consent provided by the participant.\n\nExclusion Criteria:\n\n* Patients with systemic diseases that contraindicate oral surgery or interfere with bone healing (e.g., uncontrolled diabetes, osteoporosis, hyperparathyroidism).\n* History of head and neck radiation therapy or bisphosphonate medication use.\n* Active infection or acute abscess at the extraction site.\n* Heavy smokers (more than 10 cigarettes per day).\n* Pregnant or lactating women.\n* Patients with poor oral hygiene or active periodontal disease in the rest of the mouth.\n* Use of any medications known to affect bone metabolism (e.g., long-term corticosteroids).",true,"ALL","20 Years","45 Years",{"count":22,"type":23},40,"ESTIMATED","INTERVENTIONAL",[26,27],"PHASE1","PHASE2","This study evaluates two different treatments used to help the jawbone heal after a tooth is removed. When a tooth is extracted, the surrounding bone often shrinks, which can make it difficult to place dental implants later. Currently, doctors often use Platelet-Rich Fibrin (PRF), which is made from the patient's own blood, to help the area heal.\n\nThis research compares PRF to a newer treatment using \"exosomes\" derived from stem cells. Exosomes are tiny particles that carry signals to tell the body to repair tissue and grow new bone. The goal of this study is to see if these exosomes work better than PRF at keeping the bone strong and thick after an extraction. Researchers will use specialized X-rays (CBCT) to measure the bone three months after the procedure to see which treatment provided better results.",[30,31,32],"Alveolar Bone Loss","Tooth Extraction","Bone Regeneration",[34,35,36,37,38,39,40],"MSC-derived Exosomes","Platelet-Rich Fibrin (PRF)","Alveolar Ridge Preservation","Socket Grafting","Cone-Beam Computed Tomography (CBCT)","Stem Cell Secretome","Bone Density","RECRUITING","2026-03-27",{"date":44,"type":45},"2026-04-02","ACTUAL",{"date":47,"type":45},"2026-01-15",{"date":49,"type":23},"2026-08-01",{"name":51,"class":52},"Al Salam University","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":24,"phases":65,"briefSummary":67,"conditions":68,"keywords":69,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100572353","performance-and-safety-of-lyoplant-in-guided-bone-regeneration-gbr-in-oral-surgery-100572353","NCT06732167","Performance and Safety of Lyoplant® in Guided Bone Regeneration (GBR) in Oral Surgery","Prospective, Randomized, Controlled, Multicenter Study on the Performance and Safety of Lyoplant® in Guided Bone Regeneration (GBR) in Oral Surgery","LyOral","Inclusion Criteria:\n\n* Patients who are willing to give a voluntary consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the Informed Consent Form (ICF).\n* Patients with the capacity to consent for themselves.\n* Patients in need of an implant with a simultaneous GBR procedure.\n* Presence of buccal bony dehiscence with a vertical defect height (VDH) ≥ 1 mm and ≤ 6 mm after implant placing.\n* The tooth at the implant site must have been extracted or lost at least 8 weeks before the date of bone augmentation (volumetrically healed site).\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years.\n* Currently pregnant or breastfeeding women.\n* Major systemic diseases (e.g. recent myocardial infarction, cerebrovascular accident or valvular prosthesis surgery, a poorly stabilized diabetes mellitus, severe hypertension, severe peripheral artery occlusive disease, malignancies, autoimmune diseases, or kidney diseases, untreated or uncontrolled periodontal disease, uncontrolled drug or alcohol abuse, uncontrolled psychiatric disorders).\n* Acute infectious diseases.\n* Immunocompromised patients.\n* Serious disturbances of bone metabolism and\u002For serious bone diseases of endocrine etiology.\n* Medical conditions requiring prolonged use (\\> 6 months) of steroids and\u002For ongoing treatment with gluco- and mineralocorticoids and with agents affecting calcium metabolism (e.g. calcitonin), and\u002For anticoagulative therapy.\n* Previous or current use of antiresorptive drugs (ARDs) (e.g. bisphosphonates, selective estrogen receptor modulators (SERMs), denosumab, hormone replacement therapy and calcitonin).\n* Previous oral \u002F maxillofacial radiotherapy.\n* Heavy smoker (\\>10 cigarettes\u002Fday). In the case of vapors with nicotine, the use of \\>300 puff vapors (equivalent to 10 cigarettes\u002Fday) are not allowed.\n* Health conditions, which do not permit the surgical treatment.\n* Use of the Investigational Device \u002F Comparator in infected areas.\n* Known foreign body sensitivity to implant materials.\n* Simultaneous participation in another interventional clinical trial (drugs or medical devices studies) if it could impact the result of the study.","18 Years",{"count":64,"type":23},68,[66],"NA","Guided Bone Regeneration (GBR) is a well-established surgical technique that employs barrier membranes to ensure the stability of bone augmentation material while preventing the infiltration of soft tissue, thereby facilitating new bone formation.\n\nThe primary objective of this randomized controlled trial is to assess the performance and safety of the Lyoplant® collagen membrane as a barrier membrane in GBR for patients undergoing dental implant surgery. Additionally, the study aims to compare the Lyoplant® membrane with the Bio-Gide® collagen membrane, with the goal of demonstrating the non-inferiority of the Lyoplant® membrane in terms of radiographically measured bone gain compared to the comparator.",[32],[70],"collagen barrier membrane","2026-02-24",{"date":73,"type":45},"2026-02-27",{"date":75,"type":45},"2025-01-24",{"date":77,"type":23},"2026-12",{"name":79,"class":80},"Aesculap AG","INDUSTRY",2,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100604720","creos-xenoprotect-pmcf-100604720","NCT07153185","Creos Xenoprotect PMCF","A Retrospective Multi-center, PMCF Study to Assess the Safety and Performance of a Biodegradable Dental Barrier Membrane (Creos Xenoprotect)","Inclusion Criteria:\n\n* Participant was treated before December 2023 (creos xenoprotect placement)\n\n  * Participant signed informed consent form and data protection consent form1\n  * Participant was at least 18 years old at the time of treatment\n  * Participant received guided bone regeneration combined with the use of creos xenoprotect according to one of the four indications\n  * Participant was treated according to instructions for use (IFU)\n  * Participant should have follow-up time of \\>9 months after placement of the investigational device\n\nExclusion Criteria:\n\n* In Group 3: Sinus floor augmentation (lateral approach): usage of creos xenoprotect to replace a ruptured Schneiderian Membrane",{"count":90,"type":23},200,"OBSERVATIONAL","The goal of this retrospective PMCF study is to assess safety and performance of creos xenoprotect in all indications functioning as dental barrier membrane.\n\nThe primary endpoint of the study is the occurrence of major complications during 6 months after creos xenoprotect placement whereas the hypothesis is that these major complications occur in less than 5% within this timeframe.\n\nThis is a retrospective, multicenter clinical investigation with consecutive cases. Data will be collected on consecutive data cases from patient files, given that these patients were treated within a defined indication with creos xenoprotect in the past. Patients participating in this study do not have any obligations or need to come back for any intervention. A total of 11 centers are planned to be included. Sample size is n=200 patients and is distributed equally in four indication groups:\n\nGroup 1: Ridge augmentation (vertical and horizontal) Group 2: Alveolar ridge preservation Group 3: Sinus floor augmentation Group 4: Augmentation around implant or teeth",[32,94,95],"Dental Implants","Bone Grafting",[97,98,99],"Dental Barrier Membrane","PMCF Study","Retrospective","NOT_YET_RECRUITING","2025-08-25",{"date":103,"type":45},"2025-09-03",{"date":105,"type":23},"2025-11-01",{"date":107,"type":23},"2026-07-31",{"name":109,"class":80},"Nobel Biocare",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":24,"phases":121,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":53},"100587236","effect-of-nitroglycerin-hydrogel-on-repairing-critical-bone-defects-100587236","NCT06925763","Effect of Nitroglycerin Hydrogel on Repairing Critical Bone Defects","Unlocking the Regenerative Potential: The Effect of Nitroglycerin Hydrogel on Repairing Critical Bone Defects (Experimental Study)","Nitro- Bone","Inclusion Criteria:\n\n* All animals were adult with an age ranging between 3 to 7 months and a weight ranging between 250 and 350 g\n\nExclusion Criteria:\n\n* other than inclusion","7 Months",{"count":120,"type":23},33,[66],"Due to their osteoconductive, osteoinductive, and osteogenic qualities, autologous bone grafts are the gold standard for augmenting bone, (1). However, problems, insufficient bone quantity, and\u002F or quality at the donor location could prevent it from being used. Consequently, a variety of bone graft materials, such as allografts and\u002For xenografts, were developed to improve bone development and provide an osteoconductive matrix in the so-called hard tissue critical-size defect (CSD) (2).\n\n\"critically-sized\" defect is regarded as one that would not heal spontaneously despite surgical stabilization and requires further surgical intervention (3). The management of critical-sized bone defects remains a major clinical orthopedic challenge. Critical-sized bone defects are technically defined as those that will not heal spontaneously during the patient's lifetime. Bone loss greater than 2 times the diameter of the long bone diaphysis is unlikely to result in union despite appropriate stabilization methods (4).\n\nNitroglycerin, also known as glyceryl trinitrate (GTN), is a medication commonly used to treat heart conditions like angina pectoris and chronic heart failure. It acts as a potent vasodilator, dilating the vascular system to improve blood flow. Nitroglycerin has been found to have a positive effect on bone formation. Studies indicate that Nitroglycerin when applied topically, can increase bone formation and reduce bone resorption. This effect is achieved through the stimulation of osteoblastic differentiation and proliferation (5).\n\nThe mechanism of action of Nitroglycerin in bone formation involves its conversion into nitric oxide (NO), which plays a crucial role in stimulating bone formation. Nitric oxide released from nitroglycerin acts as a signaling molecule that enhances osteoblastic differentiation and proliferation of bone marrow-derived mesenchymal stem cells. This process leads to increased bone mineral density, improved bone geometry, and enhanced bone strength (5).\n\nHydrogels are natural or synthetic biocompatible polymers that are widely used in periodontal tissue engineering as a delivery material for different biologics (6). Synthetic hydrogels have superiority in chemical and mechanical properties over natural hydrogels (7). Carbopol or polyacrylic acid (PAA) is one of the most widely used polymers as a hydrogel. It is an anionic polyelectrolyte that can be readily polymerized and crosslinked to form hydrogels with a swelling capacity greater than their dry weight (8).",[32,124,125],"Periodontal Bone Loss","Healing Fracture of Bone",[127,128,129],"nitroglycerin,","bone regeneration","critical size defect","2025-04-07",{"date":132,"type":45},"2025-04-13",{"date":134,"type":23},"2025-04-01",{"date":136,"type":23},"2025-08-01",{"name":138,"class":52},"Minia University",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":24,"phases":149,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":53},"100558561","phase-1-pilot-study-on-the-effectiveness-of-a-flexible-hydroxyapatite-based-composite-for-jaw-bone-regeneration-100558561","NCT06552715","Pilot Study on the Effectiveness of a Flexible Hydroxyapatite-Based Composite for Jaw Bone Regeneration","Pilot Clinical Study on the Efficacy of a Flexible Hydroxyapatite-Based Composite for the Regeneration of Jaw Bone Defects","Flexi2024","Inclusion Criteria:\n\n* Patients with partially edentulous and atrophic jaws, requiring implant-prosthetic rehabilitation (from 1 to 3 implants), classified as Seibert Class II or III, and needing a GBR bone regeneration intervention with defects not exceeding 7 mm in height\n* Age 18 years or older\n* Obtaining informed consent\n\nExclusion Criteria:\n\n* Patients who have received radiation therapy to the head and neck with more than 70 Gray.\n* Immunocompromised and immunosuppressed patients.\n* Patients treated with or currently receiving intravenous amino-bisphosphonates.\n* Patients with poor oral hygiene and lack of motivation.\n* Uncontrolled diabetes.\n* Pregnancy or breastfeeding.\n* Drug or alcohol dependence.\n* Psychiatric conditions that contraindicate surgical treatment.\n* Limited mouth opening (less than 3.5 cm distance between the two arches in the anterior area).\n* Patients with acute or chronic inflammation\u002Finfection at the implant site.\n* Patients referred solely for implant placement.",{"count":148,"type":23},20,[26],"Following a review of the scientific literature, it was found that there are no clinical studies but only in vitro and in vivo studies, which show promising results in terms of bone formation and integration. However, it is necessary to evaluate how well the regenerated bone maintains its structural integrity over time, considering masticatory function and real-life biomechanics. Factors such as mechanical load, remodeling dynamics, and interactions with surrounding tissues could influence the long-term stability of the regenerated bone. Additionally, another important aspect to study is the potential complications and adverse effects associated with the use of the flexible HAp-based composite.",[152,153,32],"Bone Atrophy","Edentulism",[128,155,156],"dental implants","jaws atrophy","2024-08-09",{"date":159,"type":45},"2024-08-14",{"date":161,"type":23},"2024-09",{"date":163,"type":23},"2025-09",{"name":165,"class":52},"University of Bologna",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":17,"sex":18,"minAge":62,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":24,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100545551","evaluation-of-performance-safety-and-benefit-of-the-wishbone-ha-as-bone-graft-substitute-a-pre-market-clinical-investigation-100545551","NCT06383377","Evaluation of Performance, Safety and Benefit of the Wishbone HA as Bone Graft Substitute, a Pre-market Clinical Investigation","Prospective, Multi-center, Randomized, Single Blinded and Parallel Controlled Clinical Investigation to Assess the Performance, Safety and Benefit of the Wishbone HA Medical Device, a Deproteinized Bovine Bone Material, as a Bone Graft Substitute in the Socket Management Indication Requiring Bone Grafting Procedure Before Implant Placement.","Inclusion Criteria:\n\n* The subject signed the informed consent form;\n* The subject is ≥ 18 and ≤ 80 years old at surgery;\n* The subject is in need of a tooth extraction prior to implant placement;\n* All four bony walls are preserved after extraction;\n* Minimum 8mm height of bone;\n* Minimum 7mm thickness of lingual vestibular;\n* The subject is willing and able to comply with all investigation related procedures (such as exercising oral hygiene and attending all follow-up visits);\n* Full-mouth bleeding score (FMBS) lower than 25%;\n* Full-mouth plaque score (FMPI) lower than 25%.\n\nExclusion Criteria:\n\n* Subject with an acute infection (abscess) at the surgical site;\n* Subject with untreated periodontitis or periodontal disease;\n* Subject with autoimmune diseases or subjects that had received or were currently receiving treatment with antiresorptive drugs (e.g., bisphosphonates), or steroid therapy;\n* Subject who is pregnant or breastfeeding;\n* Subjects is a heavy smoker (\\>10 cigarettes a day);\n* Subject with an inability to conduct basic oral hygiene (poor oral hygiene and motivation);\n* Subject with metabolic diseases (diabetes, hyperparathyroidism, osteomalacia);\n* Subject with severe renal dysfunction and severe liver disease;\n* Subject with known severe osteoporosis;\n* Subject with multiple sclerosis and\u002For acromegaly;\n* Subject follows radiotherapy;\n* Subject with psychiatric disorders or under substance abuse (drug or alcohol);\n* Subject who participates in other clinical trials interfering with the present protocol;\n* Mucosal diseases in the areas to be treated.","80 Years",{"count":175,"type":23},96,[66],"This investigation is a pre-market, prospective, multi-center, randomized, single blinded, parallel controlled clinical investigation performed in at least 5 clinical centers for confirmatory purposes of the use of WHA as intended in the filling of extraction sockets to enhance preservation of the alveolar socket.",[32,179],"Safety Issues","2024-05-28",{"date":182,"type":45},"2024-05-29",{"date":184,"type":45},"2024-04-26",{"date":186,"type":23},"2030-03-31",{"name":188,"class":80},"Wishbone SA",5]